Appointment of M/s. Walker Chandiok & Co LLP, Chartered Accountants as Statutory Auditor of the Company for five consecutive years commencing from conclusion of the 22nd AGM to be held ....
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Corona Remedies reported strong FY2025-26 results with revenue from operations of Rs.1,403.18 Crores, up 17% from Rs.1,196.42 Crores in the prior year. Net profit after tax grew 24% to Rs.184.85 Crores (standalone) from Rs.149.05 Crores. The Board approved appointment of Walker Chandiok & Co LLP as Statutory Auditor for 5 years starting from the 22nd AGM, replacing the previous auditor Deloitte Haskins & Sells LLP. Additionally, the Board recommended a 100% final dividend of Rs.10 per share (record date June 19, 2026) and re-appointed Dr. Kirtikumar Mehta as Non-Executive Chairman for another 5 years. The company listed on NSE and BSE in December 2025 via an IPO.
Positive shareholder returns with 100% dividend payout signal strong cash generation. Appointment of a new Big 4 auditor (Walker Chandiok) indicates routine auditor rotation post-IPO. The 24% profit growth demonstrates solid operational performance in the pharmaceutical business.